캔델 테라퓨틱스(CADL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $10.85 (-4.32%), 시가총액 $0.57B, 52주 최저~최고 $4.42 ~ $8.94.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known a
캔델 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
캔델 테라퓨틱스의 현재 주가는 $10.85 (-4.32%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
캔델 테라퓨틱스의 시가총액은 약 $0.57B입니다.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of pro